Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Pfizer, BioNTech Begin Japan PI/II Study for COVID-19 Vaccine
October 21, 2020
- Drug Promotions Collectively Down in August: Intage
October 21, 2020
- Astellas Wins FDA’s Fast-Track Tag for Primary Mitochondrial Myopathies Drug
October 21, 2020
- Sawai to Launch Zagallo Generic on Nov. 6
October 20, 2020
- Pfizer Starts Promotion for 4 Authorized Generics, Including Lyrica AG
October 20, 2020
- LEO Pharma’s Atopic Dermatitis Program Lags as PMDA Requests Japanese Data, but Growth Goal Intact
October 20, 2020
- Fujifilm Eyes Avigan Use in Mild and Severe COVID-19 Cases: Exec
October 19, 2020
- Chinese Regulators Accept Eisai’s Fycompa for Monotherapy, Additional Pediatric Use
October 19, 2020
- (Update) Avigan Filed for COVID-19 in Japan: Fujifilm
October 16, 2020
- Chugai, Roche Discussing Japan Development of Regeneron's COVID-19 Antibody Cocktail
October 16, 2020
- JPWA Raided Too over Big 4 Wholesalers’ Bid-Rigging Scandal
October 16, 2020
- Avigan Filed for COVID-19 in Japan: Fujifilm
October 16, 2020
- Evaluating Vaccine Efficacy Will Be a Challenge for COVID-19 Vaccine Development in Japan: Developers
October 16, 2020
- Chugai Files 1st Oral SMA Treatment in Japan
October 16, 2020
- Otsuka Misses Primary Goal in PIII Guadecitabine Trials
October 16, 2020
- Astellas to Snap Up US Implantable Medical Devices Startup iota
October 16, 2020
- Japan Sees Improved LHRH Agonist Supply as Leuprorelin Output Rises; Shipment Curbs for Substitutes Lifted
October 15, 2020
- Remicade Biosimilars Expand Labels into Ankylosing Spondylitis
October 15, 2020
- Takeda Links Arms with Accenture, AWS to Accelerate Digital Transformation
October 15, 2020
- Cefiderocol Demonstrated Non-Inferiority to Meropenem in Global PIII: Shionogi
October 15, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…